Rare cases of cerebral venous thrombosis after COVID-19 mRNA vaccines have been reported in real-world post-vaccination data. As phase 3 clinical mRNA vaccine trials do not aim to and are not sufficiently powered to detect rare adverse events, the risks, and benefits of new vaccines are usually not fully known during regulatory approval, particularly following emergency use authorization. A temporal relation to vaccine administration does not confirm the diagnosis of “vaccineinduced thrombosis.” In addition, available literature on postvaccination thrombosis lacks sufficient power to detect significant associations with rare events like CVT. Hence, we discuss our observations of cerebral venous thrombosis occurring after COVID-19 mRNA vaccination in Singapore.
Journal/Conference/Book title
American Journal of HematologyPublication date
2022-10-29Rights statement
This is the peer reviewed version of the following article: Fan, B. E., R. R. Ling, K. Ramanathan, B. P. L. Leung, X. R. Lim, V. M. Chadachan, U. Thirugnanam, D. Stegner, and T. M. Tu. (2022). COVID-19 mRNA vaccine associated cerebral venous thrombosis: rare adverse event or coincidence? Am J Hematol. https://doi.org/10.1002/ajh.26773, which has been published in final form at https://doi.org/10.1002/ajh.26773. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.Corresponding author
Dr Eugene Fan, bingwen_eugene_fan@ttsh.com.sg